HRP20041056B1 - Derivati 6-11 bicikličkih ketolida - Google Patents
Derivati 6-11 bicikličkih ketolidaInfo
- Publication number
- HRP20041056B1 HRP20041056B1 HR20041056A HRP20041056A HRP20041056B1 HR P20041056 B1 HRP20041056 B1 HR P20041056B1 HR 20041056 A HR20041056 A HR 20041056A HR P20041056 A HRP20041056 A HR P20041056A HR P20041056 B1 HRP20041056 B1 HR P20041056B1
- Authority
- HR
- Croatia
- Prior art keywords
- previously defined
- heteroaryl
- aryl
- substituted
- halogen
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003835 ketolide antibiotic agent Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000003107 substituted aryl group Chemical group 0.000 abstract 6
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 abstract 1
- 101100509371 Arabidopsis thaliana CHR11 gene Proteins 0.000 abstract 1
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Spoj prikazan formulom: ili njegova farmaceutski prihvatljiva sol, ester ili prolijek, naznačen time, da je A izabran od: a) -OH; b) -ORp, gdje Rp jehidroksi zaštitna skupina; c) -Rl, gdje R1 je neovisno izabran od: (1) arila; (2) supstituiranog arila; (3) heteroarila; i (4) supstituiranog heteroarila; d) -ORl, gdje R1 je kao što je prethodnodefinirano; e) -R2, gdje R2 je izabran od: (1) vodika; (2) halogena; (3) C1-C12alkila koji može sadržavati 0, 1, 2 ili 3 heteroatoma izabranih od O,S ili N, eventualno supstituiranih s jednim ili više supstituenata izabranih iz skupine koju čine halogen, aril, supstituirani aril, heteroaril i supstituirani heteroaril; (4) C2-C12alkenila koji može sadržavati 0, 1, 2 ili 3 heteroatoma izabrana odO, S i N, eventualno supstituiranih s jednim ili više supstituenata izabranih iz skupine koju čine halogen, aril, supstituirani aril, heteroaril i supstituirani heteroaril; i (5) C2-C12alkinila kojimože sadržavati 0, 1, 2 ili 3 heteroatoma izabrana od O, S i N, eventualno supstituiranih s jednim ili više supstituenata izabranih iz skupine koju čine halogen, aril, supstituirani aril, heteroaril i supstituirani heteroaril; f) -OR2, gdje R2 je neovisno prethodno definiran; g) -S(O)nR11, gdje n=0, 1 ili 2, i R11 je neovisno vodik, R1 ili R2, gdje R1 i R2 su kao što je prethodno definirano; h) -NHC(O)R11, gdje R11 je kao što je prethodno definirano; i) -NHC(O)NHR11 gdje R11 je kao što je prethodno definirano; j) -NHS(O)2R11, gdje R11 je kao što je prethodno definirano; k) -NR14R15, gdje R14 i R15 su međusobno neovisno R11, gdje R11 je kao što je prethodno definirano il) -NHR3, gdje R3 je amino zaštitna skupina; B je izabran od: a) vodika;b) deuterija; c) halogena; d) -OH; e) Rl, gdje R1je kao što je prethodno definirano; f) R2, gdje R2 je kao što je prethodno definirano; ig) -ORp, gdje Rp je kao što je prethodno definirano, osiguravajući da kada B je halogen, -OH ili -ORp, A je R1 ili R2; ili alternativno, A i B zajedno s atomom ugljika na koji su vezani, izabrani su između: a) C=O; b) C(OR2)2, gdje R2 je kao što je prethodno definirano; c) C(SR2)2, gdje R2 je kao što je prethodno definirano; d) C[-O(CH2)m]2, gdje m=2 ili 3; e) C[-S(CH2)m]2, gdje m je kao što je prethodno definirano; f) C=CHR11, gdje R11 je kao što je prethodno definirano; g) C=N-O-R11, gdje R11 je kao što je prethodno definirano; h) C=N-O-Ar1-M-Ar2, gdje(1) -Arl- je R31, gdje R31 je neovisno izabran između: (a) R1, gdje R1 je kao što je prethodno definirano; (b) C1-C12alkila koji može sadržavati 0,1, 2 ili 3 heteroatoma izabrana od O, S ili N, eventualno supstituirana s jednim ili više supstituenata izabranih iz skupine koju čine halogen, aril,supstituirani aril, heteroaril i supstituirani heteroaril; (c) C2-C12alkenila koji može sadržavati 0, 1, 2 ili 3 heteroatoma izabrana od O, S i N, eventualno supstituirana s jednim ili više supstituenata izabranih iz skupine koju čine halogen, aril,supstituirani aril, heteroaril i supstituirani heteroaril; ili
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14455802A | 2002-05-13 | 2002-05-13 | |
US10/429,485 US6878691B2 (en) | 2002-05-13 | 2003-05-05 | 6-11 bicyclic ketolide derivatives |
PCT/US2003/014669 WO2003097659A1 (en) | 2002-05-13 | 2003-05-09 | 6-11 bicyclic ketolide derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20041056A2 HRP20041056A2 (en) | 2005-06-30 |
HRP20041056B1 true HRP20041056B1 (hr) | 2009-02-28 |
Family
ID=29552703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20041056A HRP20041056B1 (hr) | 2002-05-13 | 2004-11-11 | Derivati 6-11 bicikličkih ketolida |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1506214B1 (hr) |
JP (1) | JP3821826B2 (hr) |
CN (1) | CN1633444A (hr) |
AU (1) | AU2003239403B2 (hr) |
BR (1) | BR0310050A (hr) |
CA (1) | CA2483678C (hr) |
HR (1) | HRP20041056B1 (hr) |
MX (1) | MXPA04011204A (hr) |
NZ (1) | NZ536403A (hr) |
WO (1) | WO2003097659A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135573B2 (en) | 2002-05-13 | 2006-11-14 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine |
US7910558B2 (en) | 2002-05-13 | 2011-03-22 | Enanta Pharmaceuticals, Inc. | Bridged macrocyclic compounds and processes for the preparation thereof |
US7022679B2 (en) | 2002-05-13 | 2006-04-04 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 6-11 bicyclic erythromycin derivatives |
EP1670808A1 (en) * | 2003-09-12 | 2006-06-21 | Chiron Corporation | Antimicrobial derivatives |
US7414030B2 (en) | 2004-01-07 | 2008-08-19 | Enanta Pharmaceuticals, Inc. | 6-11 Bicyclic erythromycin derivatives |
CN1910171B (zh) * | 2004-01-14 | 2011-09-28 | 伊南塔医药品股份有限公司 | 6-11双环红霉素衍生物的制备方法 |
WO2005080408A1 (en) * | 2004-01-23 | 2005-09-01 | Enanta Pharmaceuticals, Inc. | Bridged macrocyclic compounds and processes for the preparation thereof |
US7384921B2 (en) | 2004-02-20 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | Polymorphic forms of 6-11 bicyclic ketolide derivatives |
US7229972B2 (en) | 2004-12-07 | 2007-06-12 | Enanta Pharmaceuticals, Inc. | 3,6-Bicyclolides |
US7419962B2 (en) | 2004-12-07 | 2008-09-02 | Enanta Pharmaceuticals, Inc. | 3,6-bicyclolides |
TW200635600A (en) | 2004-12-13 | 2006-10-16 | Enanta Pharm Inc | Tetracyclic bicyclolides |
US7291602B2 (en) | 2004-12-13 | 2007-11-06 | Enanta Pharmaceuticals, Inc. | 11,12-lactone bicyclolides |
TW200634000A (en) * | 2004-12-22 | 2006-10-01 | Shionogi & Co | 2-(pyrazol-1-yl)pyridine derivatives |
CN101124236A (zh) * | 2005-02-21 | 2008-02-13 | 阿尔法马股份公司 | 大环内酯类的生产方法 |
US20060252710A1 (en) * | 2005-05-04 | 2006-11-09 | Guoqiang Wang | 6-11 Bridged oxime erythromycin derivatives |
CA2605295A1 (en) * | 2005-05-04 | 2006-11-09 | Enanta Pharmaceuticals, Inc. | 6-11 bridged oxime erythromycin derivatives |
US7384922B2 (en) | 2005-05-04 | 2008-06-10 | Enanta Pharmaceuticals, Inc. | 6-11 bridged oxime erythromycin derivatives |
US7589067B2 (en) | 2005-10-12 | 2009-09-15 | Enanta Pharmaceuticals, Inc. | 6, 11-bridged tricyclic macrolides |
US7407942B2 (en) | 2006-03-29 | 2008-08-05 | Emata Pharmaceuticals, Inc | 3,6-bridged 9,12-oxolides |
NZ584159A (en) * | 2007-09-17 | 2012-08-31 | Enanta Pharm Inc | 6,11-bridged biaryl macrolides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866549A (en) * | 1996-09-04 | 1999-02-02 | Abbott Laboratories | 6-O-substituted ketolides having antibacterial activity |
-
2003
- 2003-05-09 CA CA002483678A patent/CA2483678C/en not_active Expired - Fee Related
- 2003-05-09 MX MXPA04011204A patent/MXPA04011204A/es active IP Right Grant
- 2003-05-09 CN CNA038037300A patent/CN1633444A/zh active Pending
- 2003-05-09 WO PCT/US2003/014669 patent/WO2003097659A1/en active Application Filing
- 2003-05-09 EP EP03733983A patent/EP1506214B1/en not_active Expired - Lifetime
- 2003-05-09 JP JP2004506333A patent/JP3821826B2/ja not_active Expired - Fee Related
- 2003-05-09 BR BR0310050-2A patent/BR0310050A/pt not_active Application Discontinuation
- 2003-05-09 AU AU2003239403A patent/AU2003239403B2/en not_active Ceased
- 2003-05-09 NZ NZ536403A patent/NZ536403A/en not_active IP Right Cessation
-
2004
- 2004-11-11 HR HR20041056A patent/HRP20041056B1/hr not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866549A (en) * | 1996-09-04 | 1999-02-02 | Abbott Laboratories | 6-O-substituted ketolides having antibacterial activity |
Also Published As
Publication number | Publication date |
---|---|
EP1506214A1 (en) | 2005-02-16 |
WO2003097659A1 (en) | 2003-11-27 |
JP2005530803A (ja) | 2005-10-13 |
NZ536403A (en) | 2008-02-29 |
BR0310050A (pt) | 2005-05-10 |
AU2003239403B8 (en) | 2003-12-02 |
CA2483678C (en) | 2010-01-12 |
CA2483678A1 (en) | 2003-11-27 |
AU2003239403A1 (en) | 2003-12-02 |
HRP20041056A2 (en) | 2005-06-30 |
MXPA04011204A (es) | 2005-06-08 |
AU2003239403B2 (en) | 2007-01-11 |
JP3821826B2 (ja) | 2006-09-13 |
CN1633444A (zh) | 2005-06-29 |
EP1506214B1 (en) | 2010-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20041056B1 (hr) | Derivati 6-11 bicikličkih ketolida | |
UY27918A1 (es) | Derivados de benzodioxol | |
ME01421B (me) | 5-supstituisani derivati kinazolinona kao protivtumorska sredstva | |
CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
RS52865B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
MX2007005694A (es) | Nuevos derivados de betulina, preparacion y uso de los mismos. | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
HRP20050213A2 (en) | 2,4-substituted indoles and their use as 5-ht6 modulators | |
ATE370145T1 (de) | Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten | |
HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
ATE297910T1 (de) | Retinoid x rezeptormodulatoren | |
HRP20090152T3 (hr) | Disulfidni, sulfidni, sulfoksidni i sulfonski derivati cikličkih šećera i njihove upotrebe | |
RS51674B (en) | PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS | |
HRP20090162T1 (hr) | Kinolinon-karboksamidni spojevi kao agonisti 5-ht4 receptora | |
RS54700B1 (en) | INDAZOLE DERIVATIVES SUBSTITUTED WITH BENZODIOXINIL | |
DE602005027213D1 (de) | Neue imidazolidinderivate | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
HRP20070286T3 (hr) | Supstituirani diketopiperazini i njihova upotrebakao oksitocinski antagonisti | |
ECSP045420A (es) | Derivados de benzoxazina como moduladores 5-ht6 y usos de los mismos | |
BR0211972A (pt) | Composição oftálmica | |
AR058257A1 (es) | Derivados de 8-azabiciclo[3.2.1]octano. composiciones farmaceuticas. | |
RS52518B (en) | 4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS | |
RS52427B (en) | ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170426 Year of fee payment: 15 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180509 |